Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country save search
Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024
Published: 2024-04-18 (Crawled : 00:00) - biospace.com/
QSI | $1.57 3.97% 3.82% 730K
|
Professional, Scientific, and T...
|
| O: -0.65%
H: 0.0%
C: 0.0%
first report financial results
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: 1.1%
H: 0.0%
C: 0.0%
association for meeting benefits
FNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual Meeting
Published: 2024-04-17 (Crawled : 00:00) - biospace.com/
RLYB | News | $1.75 4.79% 4.57% 310K
|
|
| O: -4.44%
H: 0.0%
C: 0.0%
pharmacy review care meeting
KORU Medical Systems to Report First Quarter 2024 Financial Results on May 1, 2024
Published: 2024-04-17 (Crawled : 12:00) - biospace.com/
KRMD | $2.06 0.0% 59K
|
Health Technology
|
| O: -0.94%
H: 4.29%
C: 0.95%
first report medical financial results
Lipella Pharmaceuticals Expands its Advisory Board
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
LIPO | $0.707 -0.88% -0.89% 6.4K
|
|
| O: -0.96%
H: 5.56%
C: 4.17%
pharmaceuticals
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine
Published: 2024-04-16 (Crawled : 14:00) - biospace.com/
AMRX | $5.42 1.12% 1.11% 1.1M
|
Health Technology
|
| O: -1.08%
H: 1.09%
C: -0.55%
rtu first
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 75.34%
H: 37.73%
C: -30.58%
fda drug marburg infection designation for grants
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
IOBT | $1.47 0.0% 92K
|
|
| O: 0.65%
H: 1.92%
C: -3.21%
biotech commercialization
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 1.17%
H: 0.29%
C: -5.41%
htx-100 pharmaceuticals
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
OABI | $4.67 1.74% 1.71% 930K
|
|
| O: -1.58%
H: 1.77%
C: -0.4%
drug liver disease antibody for
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
URGN | $13.78 -3.37% -3.48% 390K
|
Health Technology
|
| O: 1.46%
H: 1.17%
C: -1.44%
ugn-103 fda drug bladder cancer for application
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7477 -7.18% -7.73% 1.7M
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
SNGX | $0.4233 -2.76% -2.83% 1M
|
Health Technology
|
| O: 3.67%
H: 0.46%
C: -19.02%
fda drug infection designation for grants
Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.11%
H: 0.38%
C: -0.04%
meeting
PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
PTCT | News S | $25.32 2.55% 2.49% 3.9M
|
Health Technology
|
| O: 2.01%
H: 1.35%
C: -0.18%
first conference therapeutics financial results
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
LEGN | $46.14 -2.08% -2.12% 1.2M
|
Health Technology
|
| O: 0.02%
H: 0.22%
C: -0.88%
first conference biotech results
Rallybio Announces Collaboration to Advance Therapeutic Solutions for Pregnant Individuals at Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
RLYB | News | $1.75 4.79% 4.57% 310K
|
|
| O: -3.03%
H: 4.38%
C: 1.87%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.21%
H: 0.0%
C: 0.0%
risk solutions for collaboration
New Publication in Brain Stimulation Confirms Full TMS Treatment Course Is VitalLack of early symptom improvement is not predictive of final responder status
Published: 2024-04-10 (Crawled : 22:00) - biospace.com/
STIM | $3.8 -0.78% -0.79% 49K
|
Health Technology
|
| O: 1.18%
H: 4.28%
C: 1.17%
publication treatment
Pfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV Disease
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: 0.73%
H: 2.49%
C: 0.11%
abrysvo disease positive risk for rsv results study
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
TRVI | $2.82 5.03% 4.79% 140K
|
Health Technology
|
| O: 2.77%
H: 1.59%
C: -8.57%
conference presentation international therapeutics
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.